Fierce Biotech

  1. GHO Capital has raised €975 million ($1.1 billion) to invest in European healthcare companies. The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.
  2. Tissium has raised €38.8 million ($42.9 million) to fund work on synthetic programmable polymers with applications in drug delivery and other areas. The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.
  3. Fierce 15 winner Kronos Bio has poached Jorge DiMartino, M.D., Ph.D., as its chief medical officer and executive vice president of clinical development.
  4. A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval next year. 
  5. The Medicines Company, fresh from its turn at the American Heart Association this weekend, has seen its shares jump on growing rumors that Swiss major Novartis may be interested in buying it out.